Objective: To analyze the proportion of SPP1+ macrophages in peripheral blood of patients with connective tissue disease complicated with interstitial lung disease (CTD-ILD) and the expression level of its expression product chemokine 18 (CCL18) in serum of patients with CTD-ILD and its clinical significance. Methods: Twenty patients with connective tissue disease (CTD) and 20 healthy people were selected as the control group, and 35 patients with newly diagnosed CTD-ILD were selected as the experimental group. The differences in the expression levels of SPP1+ macrophages and CCL18 in the experimental group and the control group were compared, and the correlation with type I collagen (COL1A1), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) was analyzed. Results: Compared with the control group, the proportion of SPP1+ macrophages in peripheral blood mononuclear cells of CTD-ILD patients was significantly increased (P＜0.05), and the content of CCL18 in serum was also significantly increased (P＜0.05). At the same time, SPP1+ macrophages and CCL18 were positively correlated with ESR, CRP, COL1A1 and lung imaging score (HRCT score) (P＜0.05), and negatively correlated with the percentage of forced vital capacity (FVC%) and the percentage of carbon monoxide diffusion (DLCO%) (P＜0.05). The area under the curve (AUC) of SPP1+ macrophages and CCL18 were 0.732 and 0.939, respectively. The AUC of the combined detection of SPP1+ macrophages and CCL18 was 0.939, the sensitivity was 93.5%, the specificity was 83.3%, and the Youden index was 0.768. Conclusion: SPP1+ macrophages and CCL18 are poor prognostic factors in patients with CTD-ILD. The combined detection of SPP1+ macrophages and CCL18 is of great significance for the prognosis of the disease.
ZHANG Lin
,
PANG Chunyan
,
WANG Yongfu
,
LU Fuai
. The level and clinical significance of SPP1+ macrophages and its expression product CCL18 in CTD-ILD[J]. Journal of Baotou Medical College, 2025
, 41(6)
: 49
-55
.
DOI: 10.16833/j.cnki.jbmc.2025.06.010
[1] Shao T, Shi X, Yang S, et al. Interstitial lung disease in connective tissue disease: Acommon lesion with heterogeneous mechanisms and treatment considerations[J].Front Immunol,2021,12:684699.
[2] 唐攀,吕程娜,吴挺挺,等.具有自身免疫特征的间质性肺炎25例临床分析[J].中华全科医学,2020,18(3):380-383.
[3] Wiertz IA, Moll SA, Seeltger B, et al. Genetic variation in CCL18 gene influences CCL18 expression and correlates with survival in idiopathic pulmonary fibrosis: Part A[J].J Clin Med,2020,9(6):1940.
[4] Morse C, Tabib T, Sembrat J, et al. Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis[J].Eur Respir J,2019,54(2):1802441.
[5] Shirakawa K, Endo J, Kataoka M, et al. MerTK Expression and ERK activation are essential for the functional maturation of osteopontin-producing reparative macrophages after myocardial infarction[J].J Am Heart Assoc,2020,9(18):e017071.
[6] Joy GM, Arbiv OA, Wong CK, et al. Prevalence, imaging patterns and risk factors ofinterstitial lungdisease in connective tissue disease: A systematic review and meta-analysis[J].Eur Respir Rev,2023,32(167):220210.
[7] 刘一平,颜菲,张榕.细胞因子在结缔组织病相关间质性肺病发病机制中作用的研究进展[J].中国免疫学杂志,2024,40(3):651-655+622.
[8] Yang S, Zhao M, Jia S. Macrophage: Key player in the pathogenesis of autoimmune diseases[J].Front Immunol, 2023,14:1080310.
[9] lv J, Gao H, Ma J, et al. Dynamicatlas of immune cells reveals multiple functional features of macrophages associated with progression of pulmonary fibrosis[J].Front Immunol,2023,14:1230266.
[10] Matsubara E, Yano H, Pan C, et al. The significance of SPP1 in lung cancers and its impact as a marker for protumor tumor-associated macrophages[J].Cancers (Basel),2023,15(8):2250.
[11] Papazoglou A, Huang M, Bulik M, et al. Epigenetic regulation of profibrotic macrophages in systemic sclerosis-associated interstitial lung disease[J].Arthritis Rheumatol,2022,74(12):2003-2014.
[12] Fu M, Shu S, Peng Z, et al. Single-Cell RNA sequencing of coronary perivascular adipose tissue from end-stage heart failure patients identifies SPP1+ macrophage subpopulation as a target for alleviating fibrosis[J].Arterioscler Thromb Vasc Biol,2023,43(11):2143-2164.
[13] Islam SA, Ling MF, Leung J, et al. Identification of human CCR8 as CCL18 receptor[J].J Exp Med,2013,210(10):1889-1898.
[14] Catusse J, Wollner S, Leick M, et al. Attenuation of CXCR4 responses by CCL18 inacute lymphocytic leukemia B cells[J]. J Cell Physiol,2010,225(3):792-800.
[15] Günther C, Bello-Fernandez C, Kopp T, et al. CCL18 is expressed in atopic dermatitisand mediates skin homing of human memory T cells[J]. J Immunol,2005,174(3):1723-1728.
[16] Cardoso AP, Pinto ML, Castro F, et al. The immunosuppressive and pro-tumor functions of CCL18 at the tumor microenvironment[J].Cytokine Growth Factor Rev,2021,60:107-119.
[17] Korbecki J, Grochans S, Gutowska I, et al. CC Chemokines in a tumor: A review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands[J].Int J Mol Sci,2020,21(20):7619.
[18] Luzina IG, Tsymbalyuk N, Choi J, et al. CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity[J].J Cell Physiol,2006,206(1):221-228.
[19] Elhai M, Hoffmann-Vold AM, Avouac J, et al. Performance of candidate serum biomarkers for ystemic Sclerosis-associated interstitial lung disease[J].Arthritis Rheumatol,2019,71(6):972-982.
[20] Zanatta E, Martini A, Depascale R, et al. CCL18 as a biomarker of interstitial lung disease (ILD) and progressive fibrosing ILD in patients with idiopathic inflammatory myopathies[J].Diagnostics (Basel),2023,13(10):1715.
[21] Valenzi E, Tabib T, Papazoglou A, et al. Disparate interferon signaling and shared aberrant basaloid cells in single-cell profiling of idiopathic pulmonary fibrosis and Systemic Sclerosis-Associated interstitial lung disease[J].Front Immunol,2021,12:595811.
[22] 王冬梅,袁宝军,高利常,等.CTD-ILD患者血清YKL-40和CCL18水平的变化及意义[J].天津医药,2023,51(2):198-202.
